Citations
1 publicationsPublications from researchers using this productDescription
Triciribine is an adenosine analog that targets protein kinase B (Akt) with an IC50 value of 130nM and has antitumor activity[1, 2]. Triciribine is a DNA synthesis inhibitor of HIV-1 with an IC50 value of 20nM[3].
In vitro, treatment of prostate cancer PC-3 cells with Triciribine (10μM) for 24h enhanced apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) and anti-CD95[4]. Treatment of bovine cumulus-oocyte complex (COC) with Triciribine (1μM) for 22h resulted in an increase in the rate of blastocyst formation and increased the in vitro yield of bovine embryos[5].
In vivo, treatment of C57BL/6 J mice with Triciribine (1, 2mg/kg/day) by intraperitoneal injection for 2 weeks significantly increased the level of low-density lipoprotein receptor (LDLR) in the liver of mice[6]. Triciribine (1mg/kg/day) was intraperitoneally injected into mice inoculated with GFP+ Huh7 cells for 14 days, which significantly inhibited the growth of tumors in mice and exerted a synergistic effect when combined with rosiglitazone[7].
References:
[1] Barrichon M, Hadi T, Wendremaire M, et al. EXPRESSION OF CONCERN: Dose‐dependent biphasic leptin‐induced proliferation is caused by non‐specific IL‐6/NF‐κB pathway activation in human myometrial cells[J]. British Journal of Pharmacology, 2015, 172(12): 2974-2990.
[2] Garrett C R, Coppola D, Wenham R M, et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT[J]. Investigational new drugs, 2011, 29: 1381-1389.
[3] KUCERA L S, IYER N P, PUCKETT S H, et al. Activity of triciribine and triciribine-5′-monophosphate against human immunodeficiency virus types 1 and 2[J]. AIDS research and human retroviruses, 1993, 9(4): 307-314.
[4] Dieterle A, Orth R, Daubrawa M, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL‐induced apoptosis[J]. International journal of cancer, 2009, 125(4): 932-941.
[5] Curcio A G, Ribeiro T I S, Gomes H F, et al. Increased in vitro production of bovine embryos resulting from oocyte maturation in the presence of triciribine, a specific inhibitor of AKT[J]. Theriogenology, 2025, 231: 222-227.
[6] Bjune K, Wierød L, Naderi S. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA[J]. Scientific Reports, 2018, 8(1): 16174.
[7] Liu L, Yang Z, Xu Y, et al. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells[J]. PloS one, 2013, 8(8): e73038.
Protocol
| Cell experiment [1]: | |
Cell lines | PC-3 cells |
Preparation Method | PC-3 cells were treated with TNF-related apoptosis inducing ligand (TRAIL) (0.1, 1, 10, or 40ng/mL) or anti-CD95 (0.1, 1, 10, or 100ng/mL) in the presence or absence of either Triciribine (10μM) or Akti-1/2 (10μM) for 24h. As control PC-3 cells were treated with Triciribine (0.1, 1, 10 or 40μM) or Akti-1/2 (0.1, 1, 10 or 40μM). Apoptosis was assessed by propidium iodide staining of hypodiploid apoptotic nuclei and flow cytometry. |
Reaction Conditions | 10μM; 24h |
Applications | Triciribine amplifies TRAIL-induced and anti-CD95-induced apoptosis in PC-3 cells. |
| Animal experiment [2]: | |
Animal models | C57BL/6 J mice |
Preparation Method | Mice were separated into three treatment groups each consisting of 4 mice. One group received i.p. Triciribine at 1mg/kg daily. A second group received daily i.p. injections of Triciribine at 2mg/kg. A third group was administered daily i.p. injections of vehicle (0.1% DMSO in PBS). Injection volumes were 100µL per mouse. Two weeks later, mice were sacrificed and livers were processed into a powder by grinding in liquid nitrogen, lysed in RIPA buffer and then analyzed by Western blotting. |
Dosage form | 1, 2mg/kg/day; 2 weeks; i.p. |
Applications | Treatment of mice with either doses of Triciribine for two weeks significantly increased the levels of hepatic Low-density lipoprotein receptor (LDLR). |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for Triciribine
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
